Cyclooxygenase - A target for colon cancer prevention

ISSN: 09530673
64Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Use of nonsteroidal anti-inflammatory drugs such as aspirin, which are known to inhibit cyclooxygenase activity, reduces the relative risk of colorectal cancer in humans by 40-50%. Animal and human studies have shown a 50-80% reduction in tumour multiplicity following treatment with a variety of nonsteroidal anti-inflammatory drugs. Two isoforms of cyclooxygenase have been described, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). In 85% of colorectal adenocarcinomas taken from humans, COX-2 levels are 2-50-fold higher than levels in adjacent normal intestinal mucosa, while COX-1 levels are unchanged. These observations raise the question: Does COX-1 or COX-2 provide a useful target for prevention or treatment of colorectal cancer?

Cite

CITATION STYLE

APA

Dubois, R. N. (2000). Cyclooxygenase - A target for colon cancer prevention. In Alimentary Pharmacology and Therapeutics, Supplement (Vol. 14, pp. 64–67).

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free